Clinical trial • Phase I • Neurology
Clinical trial in Spinal and Bulbar Muscular Atrophy
Phase I trial for Spinal and Bulbar Muscular Atrophy. 106 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Spinal and Bulbar Muscular Atrophy
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 17-11-2025
- First CTIS Authorization Date
- 24-12-2025
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 106
Eligibility
Recruits 106 Vulnerable population not selected; no specific consent or assent handling described in the record..
- Vulnerable Population
- Vulnerable population not selected; no specific consent or assent handling described in the record.
Recruitment
- Planned Sample Size
- 106
- Recruitment Window Months
- 22
- Consent Approach
- No consent or assent process details provided in the record.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 106
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-12-2025
- Latest Decision Or Authorization Date
- 20-03-2026
- Processing Time Days
- 88
- Number Of Sites
- 1
- Number Of Participants
- 106
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Neurology
- Contact Person Name
- Philip Kremer
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Arvinas Operations Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- Clenbuterol hydrochloride for Spinal and bulbar muscular atrophy
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease